home / stock / ubx / ubx news


UBX News and Press, Unity Biotechnology Inc. From 08/08/23

Stock Information

Company Name: Unity Biotechnology Inc.
Stock Symbol: UBX
Market: NASDAQ
Website: unitybiotechnology.com

Menu

UBX UBX Quote UBX Short UBX News UBX Articles UBX Message Board
Get UBX Alerts

News, Short Squeeze, Breakout and More Instantly...

UBX - UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2023. “We...

UBX - UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)

Phase 2b trial is a randomized, double-masked, active-controlled study designed to evaluate the safety and efficacy of UBX1325 (foselutoclax) compared to aflibercept over 24 weeks First novel senolytic therapeutic candidate to be evaluated head-to-head against standard of care anti-...

UBX - Unity Biotechnology GAAP EPS of -$0.76

2023-05-09 17:43:10 ET Unity Biotechnology press release ( NASDAQ: UBX ): Q1 GAAP EPS of -$0.76. Cash, cash equivalents and marketable securities totaled $83.4 million as of March 31, 2023 compared with $94.8 million as of December 31, 2022. UNITY believes that current cas...

UBX - UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results and Business Updates

SOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2023. “The...

UBX - UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema

A single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity ( BCVA) of +6.2 ETDRS letters from baseline at 48 weeks Approximately 53% of UBX1325-treated patients did not require any additional injecti...

UBX - UBX, OBLG and PRST among mid-day movers

2023-04-17 13:18:04 ET Gainers: Presto Automation ( PRST ) +183% . Windtree Therapeutics ( WINT ) +175% . Blackboxstocks ( BLBX ) +125% . Prometheus Biosciences ( RXDX ) +69% . Peakstone Realty Trust ( PKST ) +46% . Dragonfly...

UBX - Unity Biotech's chief medical officer Jamie Dananberg to exit company

2023-04-11 16:25:47 ET Unity Biotechnology ( NASDAQ: UBX ) said its chief medical officer Jamie Dananberg would leave the company, effective April 30. The company said Dananberg  would receive a severance payment equal to nine months of his base salary and continued ...

UBX - AAOI, CMPR and WISA among mid-day movers

2023-03-27 13:06:40 ET Gainers: WiSA Technologies ( WISA ) +93% . First Citizens BancShares ( FCNCA ) +50% . Alimera Sciences ( ALIM ) +38% . Cimpress ( CMPR ) +30% . Gorilla Technology Group ( GRRR ) +25% . CBL International...

UBX - Pharming Group, NuCana, Motorsport Games among premarket losers' pack

2023-03-27 08:52:49 ET Unity Biotechnology UBX -47% after mid-stage setback for wet AMD candidate . NuCana ( NCNA ) -28% after the European Patent Office issues oral ruling that NuCana's '190 patent is not valid . Pharming Group PHAR -13% erasing today'...

UBX - Unity Biotech sheds 48% after mid-stage setback for wet AMD candidate

2023-03-27 08:32:38 ET Unity Biotechnology ( NASDAQ: UBX ) lost ~48% pre-market Monday after announcing that its lead candidate UBX1325 failed to outperform Regeneron’s ( REGN ) blockbuster eye therapy aflibercept in a Phase 2 trial for wet age-related macular deg...

Previous 10 Next 10